Hidden Drug Resistant HIV to Emerge in the Era of Universal Treatment Access in Southeast Asia
Author(s) -
Alexander Hoare,
Stephen J. Kerr,
Kiat Ruxrungtham,
Jintanat Ananworanich,
Matthew Law,
David A. Cooper,
Praphan Phanuphak,
David P. Wilson
Publication year - 2010
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0010981
Subject(s) - drug resistance , viral load , antiretroviral therapy , transmission (telecommunications) , medicine , human immunodeficiency virus (hiv) , virology , universal design , drug , second line , first line , demography , immunology , biology , pharmacology , computer science , genetics , telecommunications , sociology , world wide web
Background Universal access to first-line antiretroviral therapy (ART) for HIV infection is becoming more of a reality in most low and middle income countries in Asia. However, second-line therapies are relatively scarce. Methods and Findings We developed a mathematical model of an HIV epidemic in a Southeast Asian setting and used it to forecast the impact of treatment plans, without second-line options, on the potential degree of acquisition and transmission of drug resistant HIV strains. We show that after 10 years of universal treatment access, up to 20% of treatment-naïve individuals with HIV may have drug-resistant strains but it depends on the relative fitness of viral strains. Conclusions If viral load testing of people on ART is carried out on a yearly basis and virological failure leads to effective second-line therapy, then transmitted drug resistance could be reduced by 80%. Greater efforts are required for minimizing first-line failure, to detect virological failure earlier, and to procure access to second-line therapies.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom